Neuralink Employees Eye Stock Sales Amidst Valuation Surge

Elon Musk's Neuralink employees are gearing up to sell company stock following a valuation jump due to its first human trial. The company is expected to launch a tender offer soon. Secondary market trades indicate increased value, though Neuralink prefers controlled tender offers to avoid regulatory issues and maintain investor exclusivity.

Elon Musk's company Neuralink is witnessing preparations among its staff to sell their stock after the brain implant firm saw a valuation surge due to its first human trial, sources revealed. Stock compensation is a strong motivator for employees at startups like Neuralink, whose shares aren't publicly traded, requiring complex private market maneuvers for liquidity.

According to sources who requested anonymity, Neuralink may launch a tender offer next month to buy back shares from employees wanting to sell. Both Musk and Neuralink have not commented on the matter. The valuation uptick was evident as the firm's secondary market trades showed a rise to values around $8 billion, double last year's worth.

The first human trial was deemed successful, with plans to expand trials to Britain and Canada. Sources note that Neuralink previously launched a tender offer at $19 per share, when secondary market trades went up to $35. Musk's other ventures like SpaceX also maintain stock scarcity, making them appealing despite limited information disclosure.

(With inputs from agencies.)